Selinexor (combination therapy)

Phase 3

47%

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

Dec 2025~

KPTI⭐Phase 3Phase 3

Selinexor (combination therapy) Phase 3 Results Expected

Selinexor (combination therapy) • Relapsed/Refractory Diffuse Large B-cell Lymphoma

Drug Information

Target Indication

Relapsed/Refractory Diffuse Large B-cell Lymphoma

Clinical Trial

Last updated: 12/4/2025